The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Current development of mTOR inhibitors as anticancer agents
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chandrasekar, N., Mohanam, S., Gujrati, M., Olivero, W. C., Dinh, D. H., & Rao, J. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206164 · Cited by 103
RetractedJ Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,665
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
(2016) · Lung Transplantation · doi:10.3109/9781439802571-25 · Cited by 2,157
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E., & Pollak, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10384-1 · Cited by 1,823
Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
Inhibition of Macroautophagy Triggers Apoptosis
Boya, P., González-Polo, R.-A., Casares, N., Perfettini, J.-L., Dessen, P., Larochette, N., Métivier, D., Meley, D., Souquere, S., Yoshimori, T., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.3.1025-1040.2005 · Cited by 1,625
Self-citationRole of the Insulin-Like Growth Factor Family in Cancer Development and Progression
Yu, H. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.18.1472 · Cited by 1,424
Lysosomes and autophagy in cell death control
Kroemer, G., & Jäättelä, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1738 · Cited by 1,285
Self-citationThe coordinate regulation of the p53 and mTOR pathways in cells
Feng, Z., Zhang, H., Levine, A. J., & Jin, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502857102 · Cited by 1,235
Larue, L., & Bellacosa, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209091 · Cited by 1,228
The MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185
RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1
Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., & Sabatini, D. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1432 · Cited by 1,138
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Dysregulation of the TSC-mTOR pathway in human disease
Inoki, K., Corradetti, M. N., & Guan, K.-L. (2005) · Nature Genetics · doi:10.1038/ng1494 · Cited by 972
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.185 · Cited by 942
NAVÉ, B. T., Ouwens, D. M., Withers, D. J., Alessi, D. R., & Shepherd, P. R. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3440427 · Cited by 932
Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M.-H., Massague, J., Crabtree, G. R., & Roberts, J. M. (1994) · Nature · doi:10.1038/372570a0 · Cited by 889
Gingras, A.-C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., & Hay, N. (1998) · Genes & Development · doi:10.1101/gad.12.4.502 · Cited by 886
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., Mansukhani, M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 875
Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin
Brunn, G. J., Hudson, C. C., Sekulić, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., & Abraham, R. T. (1997) · Science · doi:10.1126/science.277.5322.99 · Cited by 846
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
The Akt-mTOR tango and its relevance to cancer
Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 821
Sun, S.-Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 802
Shah, O. J., Wang, Z., & Hunter, T. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 798
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 736
PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase
Chung, J., Grammar, T. C., Lemon, K. P., Kazlauskas, A., & Blenis, J. (1994) · Nature · doi:10.1038/370071a0 · Cited by 719
Initiation of Protein Synthesis in Eukaryotic Cells
Pain, V. M. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.00747.x · Cited by 707
Control of p70 S6 kinase by kinase activity of FRAP in vivo
Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Bum Shin, T., & Schreiber, S. L. (1995) · Nature · doi:10.1038/377441a0 · Cited by 705
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation.
Beretta, L., Gingras, A. C., Svitkin, Y. V., Hall, M. N., & Sonenberg, N. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00398.x · Cited by 677
The mRNA 5′ cap-binding protein eIF4E and control of cell growth
Sonenberg, N., & Gingras, A.-C. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80150-6 · Cited by 673
Kauffman, H. M., Cherikh, W. S., Cheng, Y., Hanto, D. W., & Kahan, B. D. (2005) · Transplantation · doi:10.1097/01.tp.0000184006.43152.8d · Cited by 621
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
Self-citationHypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604
The NF1 tumor suppressor critically regulates TSC2 and mTOR
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 601
Ras-Dependent Induction of Cellular Responses by Constitutively Active Phosphatidylinositol-3 Kinase
Hu, Q., Klippel, A., Muslin, A. J., Fantl, W. J., & Williams, L. T. (1995) · Science · doi:10.1126/science.7701328 · Cited by 548
Takeuchi, H., Kondo, Y., Fujiwara, K., Kanzawa, T., Aoki, H., Mills, G. B., & Kondo, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3640 · Cited by 534
Regulation of eIF-4E BP1 Phosphorylation by mTOR
Hara, K., Yonezawa, K., Kozlowski, M. T., Sugimoto, T., Andrabi, K., Weng, Q.-P., Kasuga, M., Nishimoto, I., & Avruch, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26457 · Cited by 527
An expanding role for mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.06.007 · Cited by 523
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
Witzig, T. E., Geyer, S. M., Ghobrial, I., Inwards, D. J., Fonseca, R., Kurtin, P., Ansell, S. M., Luyun, R., Flynn, P. J., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.466 · Cited by 514
Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A., & Armand, J.-P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.116 · Cited by 499
Self-citationThe Akt/PKB pathway: molecular target for cancer drug discovery
Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., & Nicosia, S. V. (2005) · Oncogene · doi:10.1038/sj.onc.1209088 · Cited by 498
Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases.
Di Como, C. J., & Arndt, K. T. (1996) · Genes & Development · doi:10.1101/gad.10.15.1904 · Cited by 494
The expanding TOR signaling network
Martin, D. E., & Hall, M. N. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.02.008 · Cited by 494
Gallo, R., Padurean, A., Jayaraman, T., Marx, S., Roque, M., Adelman, S., Chesebro, J., Fallon, J., Fuster, V., Marks, A., et al. (1999) · Circulation · doi:10.1161/01.cir.99.16.2164 · Cited by 490
Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O’Reilly, T., Natt, F., Hall, J., Lane, H. A., & Thomas, G. (2005) · Cell · doi:10.1016/j.cell.2004.12.040 · Cited by 486
Scott, P. H., Brunn, G. J., Kohn, A. D., Roth, R. A., & Lawrence, J. C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7772 · Cited by 479
Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.66.130 · Cited by 468
TOR signalling and control of cell growth
Thomas, G., & Hall, M. N. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80078-6 · Cited by 462
AMPK, the metabolic syndrome and cancer
Luo, Z., Saha, A. K., Xiang, X., & Ruderman, N. B. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.011 · Cited by 426
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I., & Boyd, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2142 · Cited by 422
Rousseau, D., Kaspar, R., Rosenwald, I., Gehrke, L., & Sonenberg, N. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.3.1065 · Cited by 399
The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling
Virolle, T., Adamson, E. D., Baron, V., Birle, D., Mercola, D., Mustelin, T., & de Belle, I. (2001) · Nature Cell Biology · doi:10.1038/ncb1201-1124 · Cited by 399
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, S. M., Wen, P., Cloughesy, T., Greenberg, H., Schiff, D., Conrad, C., Fink, K., Robins, H. I., De Angelis, L., Raizer, J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 395
deGraffenried, L. A., Friedrichs, W. E., Russell, D. H., Donzis, E. J., Middleton, A. K., Silva, J. M., Roth, R. A., & Hidalgo, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0035 · Cited by 387
Humar, R., Kiefer, F. N., Berns, H., Resink, T. J., & Battegay, E. J. (2002) · The FASEB Journal · doi:10.1096/fj.01-0658com · Cited by 381
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., & Loeffler, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.193 · Cited by 377
Distinctive activation mechanisms and functions for protein kinase Cδ
STEINBERG, S. F. (2004) · Biochemical Journal · doi:10.1042/bj20040704 · Cited by 376
Hashemolhosseini, S., Nagamine, Y., Morley, S. J., Desrivières, S., Mercep, L., & Ferrari, S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14424 · Cited by 342
The prevalence of PIK3CA mutations in gastric and colon cancer
Velho, S., Oliveira, C., Ferreira, A., Ferreira, A. C., Suriano, G., Schwartz, S., Duval, A., Carneiro, F., Machado, J. C., Hamelin, R., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.022 · Cited by 341
Li, X., Alafuzoff, I., Soininen, H., Winblad, B., & Pei, J. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.04833.x · Cited by 324
Boulay, A., Zumstein-Mecker, S., Stephan, C., Beuvink, I., Zilbermann, F., Haller, R., Tobler, S., Heusser, C., O’Reilly, T., Stolz, B., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-3554-2 · Cited by 318
Hand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case Series
Bardia, A., Loprinzi, C. L., & Goetz, M. P. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1143 · Cited by 312
Hosoi, H., Dilling, M. B., Shikata, T., Liu, L. N., Shu, L., Ashmun, R. A., Germain, G. S., Abraham, R. T., & Houghton, P. J. (1999) · PubMed · Cited by 310
Decaudin, D., Geley, S., Hirsch, T., Castedo, M., Marchetti, P., Macho, A., Kofler, R., & Kroemer, G. (1997) · PubMed · Cited by 297
Self-citationInsulin-like growth factor physiology and cancer risk
Pollak, M. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00102-7 · Cited by 296
The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis
Hamada, K., Sasaki, T., Koni, P. A., Natsui, M., Kishimoto, H., Sasaki, J., Yajima, N., Horie, Y., Hasegawa, G., Naito, M., et al. (2005) · Genes & Development · doi:10.1101/gad.1308805 · Cited by 287
Rosenwald, I. B., Kaspar, R., Rousseau, D., Gehrke, L., Leboulch, P., Chen, J.-J., Schmidt, E. V., Sonenberg, N., & London, I. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.36.21176 · Cited by 269
(2003) · PubMed · Cited by 269
AKT activation predicts outcome in breast cancer patients treated with tamoxifen
Kirkegaard, T., Witton, C. J., McGlynn, L. M., Tovey, S. M., Dunne, B., Lyon, A., & Bartlett, J. M. (2005) · The Journal of Pathology · doi:10.1002/path.1829 · Cited by 268
Molecular mechanisms for the control of translation by insulin
PROUD, G. C., & DENTON, M. R. (1997) · Biochemical Journal · doi:10.1042/bj3280329 · Cited by 257
Dennis, P. B., Pullen, N., Kozma, S. C., & Thomas, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.11.6242 · Cited by 248
Gschwendt, M. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00120.x · Cited by 243
Marsit, C. J., Zheng, S., Aldape, K., Hinds, P. W., Nelson, H. H., Wiencke, J. K., & Kelsey, K. T. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.05.006 · Cited by 243
von Manteuffel, S. R., Gingras, A. C., Ming, X. F., Sonenberg, N., & Thomas, G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4076 · Cited by 239
Control of PHAS-I by Insulin in 3T3-L1 Adipocytes
Lin, T.-A., Kong, X., Saltiel, A. R., Blackshear, P. J., & Lawrence, J. C. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.31.18531 · Cited by 238
Buscà, R., Bertolotto, C., Ortonne, J.-P., & Ballotti, R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.31824 · Cited by 231
Mammalian Target of Rapamycin (mTOR): Pro- and Anti-Apoptotic
Castedo, M., Ferri, K. F., & Kroemer, G. (2002) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400978 · Cited by 230
Self-citationRapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
Shi, Y., Frankel, A., Radvanyi, L. G., Penn, L. Z., Miller, R. G., & Mills, G. B. (1995) · PubMed · Cited by 225
The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth.
Rousseau, D. L., Gingras, A., Pause, A., & Sonenberg, N. (1996) · PubMed · Cited by 220
Graves, L. M., Bornfeldt, K. E., Argast, G. M., Krebs, E. G., Kong, X., Lin, T. A., & Lawrence, J. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7222 · Cited by 220
Mendez, R., Myers, M. G., White, M. F., & Rhoads, R. E. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.6.2857 · Cited by 218
Gene amplifications associated with the development of hormone-resistant prostate cancer.
Edwards, J., Krishna, N. S., Witton, C. J., & Bartlett, J. M. S. (2003) · PubMed · Cited by 213
Murata, K., Wu, J., & Brautigan, D. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10624 · Cited by 211
Rapamycin Resistance Tied to Defective Regulation of p27 Kip1
Luo, Y., Marx, S. O., Kiyokawa, H., Koff, A., Massagué, J., & Marks, A. R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6744 · Cited by 210
Grewe, M., Gansauge, F., Schmid, R. M., Adler, G., & Seufferlein, T. T. W. (1999) · PubMed · Cited by 209
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., O’Toole, T., Kong, S., & Moore, L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.lba4 · Cited by 209
Shinjyo, T., Kuribara, R., Inukai, T., Hosoi, H., Kinoshita, T., Miyajima, A., Houghton, P. J., Look, A. T., Ozawa, K., & Inaba, T. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.3.854-864.2001 · Cited by 206
Fadden, P., Haystead, T. A. J., & Lawrence, J. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.15.10240 · Cited by 195
Herbert, T. P., Tee, A. R., & Proud, C. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110367200 · Cited by 181
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba, J. M., deGraffenried, L. A., Friedrichs, W. E., Fulcher, L. C., Grünwald, V., Weiss, G. R., & Hidalgo, M. M. (2003) · PubMed · Cited by 175
Frequent activation of AKT2 kinase in human pancreatic carcinomas
Altomare, D. A., Tanno, S., De Rienzo, A., Klein‐Szanto, A. J., Tanno, S., Skele, K. L., Hoffman, J. P., & Testa, J. R. (2002) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10287 · Cited by 174
Arsham, A. M., Plas, D. R., Thompson, C. B., & Simon, M. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111162200 · Cited by 174
Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer
Oki, E., Baba, H., Tokunaga, E., Nakamura, T., Ueda, N., Futatsugi, M., Mashino, K., Yamamoto, M., Ikebe, M., Kakeji, Y., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21170 · Cited by 173
Seufferlein, T., & Rozengurt, E. (1996) · PubMed · Cited by 169
Brunn, G. J., Fadden, P., Haystead, T. A. J., & Lawrence, J. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.51.32547 · Cited by 168
Efficacy of a rapamycin analog (CCI‐779) and IFN‐γ in tuberous sclerosis mouse models
Lee, L., Sudentas, P., Donohue, B., Asrican, K., Worku, A., Walker, V., Sun, Y., Schmidt, K., Albert, M. S., El‐Hashemite, N., et al. (2005) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20118 · Cited by 167
Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.
Kanamori, Y., Kigawa, J., Itamochi, H., Shimada, M., Takahashi, M., Kamazawa, S., Sato, S., Akeshima, R., & Terakawa, N. (2001) · PubMed · Cited by 165
Mutations of PIK3CAin gastric adenocarcinoma
Li, V. S. W., Wong, C. W., Chan, T. L., Chan, A. S. W., Zhao, W., Chu, K.-M., So, S., Chen, X., Yuen, S. T., & Leung, S. Y. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-29 · Cited by 164
Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors.
Okami, K., Wu, L. J., Riggins, G. J., Cairns, P., Goggins, M., Evron, E., Halachmi, N., Ahrendt, S. A., Reed, A. L., Hilgers, W., et al. (1998) · PubMed · Cited by 163
Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV‐1 envelope
Castedo, M., Roumier, T., Blanco, J., Ferri, K. F., Barretina, J., Tintignac, L. A. J., Andréau, K., Perfettini, J., Amendola, A., Nardacci, R., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf391 · Cited by 151
Self-citationPhosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?
Fry, M. (2001) · Breast Cancer Research · doi:10.1186/bcr312 · Cited by 148
Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen
Shoman, N. M., Klassen, S., McFadden, A., Bickis, M., Torlakovic, E., & Chibbar, R. (2004) · Modern Pathology · doi:10.1038/modpathol.3800296 · Cited by 142
Morice, W. G., Wiederrecht, G., Brunn, G. J., Siekierka, J. J., & Abraham, R. T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41589-x · Cited by 139
Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update
Trepanier, D. J., Gallant, H. L., LeGatt, D. F., et al. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00048-4 · Cited by 137
Kokubo, Y., Gemma, A., Noro, R., Seike, M., Kataoka, K., Matsuda, K., Okano, T., Minegishi, Y., Yoshimura, A., Shibuya, M., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602559 · Cited by 137
The Upregulation of p27Kip1 by Rapamycin Results in G1 Arrest in Exponentially Growing T-Cell Lines
Kawamata, S., Sakaida, H., Hori, T., Maeda, M., & Uchiyama, T. (1998) · Blood · doi:10.1182/blood.v91.2.561 · Cited by 117
Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma
Khaleghpour, K., Li, Y., Banville, D., Yu, Z., & Shen, S. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg195 · Cited by 112
Silencing of the PTEN tumor‐suppressor gene in anaplastic thyroid cancer
Frisk, T., Foukakis, T., Dwight, T., Lundberg, J., Höög, A., Wallin, G., Eng, C., Zedenius, J., & Larsson, C. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10098 · Cited by 107
Role of Glycogen Synthase Kinase 3β in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity
Dong, J., Peng, J., Zhang, H., Mondesire, W. H., Jian, W., Mills, G. B., Hung, M., & Meric‐Bernstam, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2501 · Cited by 104
Expression level of Bcl-2 determines anti- or proapoptotic function.
Shinoura, N., Yoshida, Y., Nishimura, M., Muramatsu, Y., Asai, A., Kirino, T., & Hamada, H. (1999) · PubMed · Cited by 104
A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
Amato, R. J., Misellati, A., Khan, M., & Chiang, S. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.4530 · Cited by 104
White, R. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(96)10067-0 · Cited by 103
Tsutsui, S., Inoue, H., Yasuda, K., Suzuki, K., Higashi, H., Era, S., & Mori, M. (2005) · Oncology · doi:10.1159/000086981 · Cited by 101
Insulin-like growth factors and breast cancer
Lee, A., & Yee, D. (1995) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(96)82678-3 · Cited by 100
Dilling, M. B., Germain, G. S., Dudkin, L., Jayaraman, A. L., Zhang, X., Harwood, F. C., & Houghton, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110782200 · Cited by 98
Epigenetic and genetic alternation of PTEN in cervical neoplasm
CHEUNG, T., LO, K., Yim, S. S., CHAN, L., Heung, M. M. S., CHAN, C., Cheung, A., Chung, T. K. H., & WONG, Y. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.03.013 · Cited by 97
Modulation of transcription of rRNA genes by rapamycin
Mahajan, P. B. (1994) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(94)90091-4 · Cited by 93
Trisciuoglio, D., Iervolino, A., Zupi, G., & Bufalo, D. D. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-12-1087 · Cited by 93
Begum, N., & Ragolia, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31166 · Cited by 90
Regulation of Ribosomal S6 Kinase 2 by Mammalian Target of Rapamycin
Park, I., Bachmann, R. A., Shirazi, H., & Chen, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204080200 · Cited by 89
Cancer and insulin-like growth factor-I
Smith, G. D. (2000) · BMJ · doi:10.1136/bmj.321.7265.847 · Cited by 87
Agbunag, C., & Bar‐Sagi, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0807 · Cited by 85
Allelic imbalance and mutations of thePTEN gene in ovarian cancer
Saito, M., Okamoto, A., Kohno, T., Takakura, S., Shinozaki, H., Isonishi, S., Yasuhara, T., Yoshimura, T., Ohtake, Y., Ochiai, K., et al. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000115)85:2<160::aid-ijc2>3.0.co;2-5 · Cited by 82
de Aguirre, Boya, P., Bellet, D. H., Faivre, S. J., Troalen, F., Bénard, J., Saulnier, P., Hopkins-Donaldson, S., Zangemeister‐Wittke, U., Kroemer, G., et al. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000045781.46314.e2 · Cited by 78
Self-citationIRS-1: Auditing the effectiveness of mTOR inhibitors
Easton, J. B., Kurmasheva, R. T., & Houghton, P. J. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.027 · Cited by 70
Harima, Y., Sawada, S., Nagata, K., Sougawa, M., Ostapenko, V., & Ohnishi, T. (2001) · International Journal of Oncology · doi:10.3892/ijo.18.3.493 · Cited by 64
Tabernero, J. M., Rojo, F., Burris, H. A., Casado, E., Macarulla, T. M., Jones, S. F., Dimitrijević, S., Hazell, K., Shand, N., & Baselga, J. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3007 · Cited by 62
Rapamycin reduces hybridoma cell death and enhances monoclonal antibody production.
Balcarcel, R., & Stephanopoulos, G. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1020 · Cited by 61
Köksal, İ. T., Dirice, E., Yasar, D., Şanlioğlu, A. D., Çiftçioğlu, A., Gülkesen, K. H., Özeş, N. O., Baykara, M., Lüleci, G., & Şanlıoğlu, S. (2004) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2004.01.009 · Cited by 60
Lee, H., Srinivas, H., Xia, D., Lu, Y., Superty, R., LaPushin, R., Gomez‐Manzano, C., Gal, A., Walsh, G. L., Force, T. L., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300997200 · Cited by 58
Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase
Calastretti, A., Bevilacqua, A., Ceriani, C., Viganò, S., Zancai, P., Capaccioli, S., & Nicolin, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204751 · Cited by 55
Marks, F., & Gschwendt, M. (1996) · Wiley eBooks · doi:10.1002/9783527615032.ch3 · Cited by 52
Characterization of Cell Death Pathways in Human Immunodeficiency Virus-Associated Encephalitis
Nardacci, R., Antinori, A., Larocca, L. M., Arena, V., Amendola, A., Perfettini, J., Kroemer, G., & Piacentini, M. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62044-5 · Cited by 36
Self-citationPhosphatidylinositol 3′ Kinase Signaling in Mammary Tumorigenesis
Scheid, M. P., & Woodgett, J. R. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1009520616247 · Cited by 36
Aoki, K., Ogawa, T., Ito, Y., & Nakashima, S. (2004) · Oncology Reports · doi:10.3892/or.11.2.375 · Cited by 32
Therapeutic Monitoring of Rapamycin
Yatscoff, R. W., LeGatt, D. F., & Kneteman, N. M. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199312000-00004 · Cited by 31
Ma, D. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i29.4472 · Cited by 28
Tell, G., Pines, A., Arturi, F., Cesaratto, L., Adamson, E. D., Puppin, C., Presta, I., Russo, D., Filetti, S., & Damante, G. (2004) · Endocrinology · doi:10.1210/en.2004-0282 · Cited by 28
Mutation Analysis of the Putative Tumor Suppressor Gene PTEN/MMAC1 in Cervical Cancer
Su, T.-H., Chang, J.-G., Perng, L.-I., Chang, C., Wei, H., Wang, N. M., & Tsai, C. (2000) · Gynecologic Oncology · doi:10.1006/gyno.1999.5659 · Cited by 27
TOR signaling and control of cell growth
Hall, M. N. (2007) · The FASEB Journal · doi:10.1096/fasebj.21.5.a206-c · Cited by 24
Use of rapamycin-impregnated stents in coronary arteries
Sousa, J. E., Sousa, A. G. M. R., Costa, M. A., Abizaid, A., & Feres, F. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00215-x · Cited by 24
DAVIES, C. B., Madden, R., ALEXANDER, J. W., Cofer, B. R., FISHER, R. A., & ANDERSON, P. (1993) · Transplantation · doi:10.1097/00007890-199305000-00033 · Cited by 23
Cited by
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Self-citationMTOR: a pharmacologic target for autophagy regulation
Kim, Y. C., & Guan, K.-L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73939 · Cited by 2,126
Metadata
- Authors
- Faivre, S., Kroemer, G., & Raymond, E.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-08-01
- Volume
- 5
- Issue
- 8
- Pages
- 671-688
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1995197723
- Cited by
- 1,000
- References
- 154
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.